August 27th 2025
FDA approves updated COVID-19 vaccines for 2025-2026 but limits pediatric access, restricting use to older and high-risk groups.
August 23rd 2025
Immune surveillance study shows pandemic interventions suppressed viral exposure in children, driving post-COVID resurgence and future outbreak risk.
August 22nd 2025
Low-dose methylprednisolone is as effective as high-dose for severe pediatric MPP and has fewer side effects, supporting safer treatment strategies.
August 20th 2025
Biennial HPV testing and higher vaccination rates could help South Korea eliminate cervical cancer up to a decade earlier than current policy.
The baby had mild respiratory distress after delivery and briefly required supplemental blow-by oxygen during transitioning.
CMV linked to increased necrotizing enterocolitis severity in premature infants
Cytomegalovirus (CMV) may worsen necrotizing enterocolitis (NEC) in premature infants, leading to severe intestinal damage.
Tina Tan, MD, comments on the measles outbreak in Texas, vaccine-preventable diseases
"The measles outbreak that is currently happening in Texas and New Mexico is occurring in an area of the states that have very high anti-vaccine sentiments," Tan said.
Breaking down invasive meningococcal disease vaccines, including Penmenvy
Amin Barakat, MD, FAAP, details meningococcal disease vaccines and highlights the recently FDA-approved MenABCWY vaccine from GSK.
RSV prevention strategies show high uptake, positive outcomes
Study findings underscore the effectiveness of a dual approach to RSV prevention.
Reacting to the meningococcal ABCWY vaccine approval with Donna Hallas, PhD, PPCNP-BC
Nurse practitioner Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN offers her thoughts on the recent FDA approval of GSK's meningococcal ABCWY vaccine.
FDA approves GSK's meningococcal ABCWY vaccine
The combination vaccine targets 5 groups of the bacteria Neisseria meningitidis (A,B,C,W, AND Y) that cause the most invasive meningococcal disease cases (IMD) globally.
Study: Most children recover within 6 months after severe MIS-C following COVID-19 infection
Most children with MIS-C recover within 6 months, with heart function and overall health improving significantly, according to a new study.
Atypical presentations of Mycoplasma pneumoniae amid a local outbreak
M pneumoniae infection is not a reportable disease, and testing is often not performed in the outpatient setting, limiting estimates of clinical prevalence and delaying recognition of community epidemics.
Experts: Now is the time to be the biggest child health care advocate
In this discussion, leading experts weigh in on the importance of scientific integrity, proactive advocacy, and the crucial role of vaccinations in pediatric health.
Weekly review: Changing atopic dermatology treatments, new puzzler, more
Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.
Tina Tan, MD, comments on a severe respiratory season, stresses timely vaccination
Tina Tan, MD, FAAP, FIDSA, FPIDS, discusses the severity of the current respiratory virus season and stresses the importance of vaccinations to protect against influenza, COVID-19, RSV, and more.
A preview of the January/February 2025 issue of Contemporary Pediatrics
Editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, highlights the January/February, 2025, issue of Contemporary Pediatrics.
Tina Tan, MD discusses the increased outbreaks of norovirus this year
Based on recent reports, norovirus outbreaks in the 2024-2025 seasonal year is above the range reported from the 2012-2020 and 2021-2024 seasonal years.
AAP: These tips can keep kids comfortable amid cold & flu season
During the current cold and flu season, children have a higher risk of getting sick. The AAP has release tips and reminders for parents to help keep children comfortable and healthy.
Discussing pediatric vaccination with vaccine-hesitant parents
Robert Frenck, MD, offers several practical tips to use when discussing pediatric vaccination among vaccine-hesitant parents.
Despite decreases of invalid vaccine doses, series completion still lacks
Of those with a minimum age or minimum interval vaccine dose, 44.9% ended up receiving extra doses to complete a vaccination series.
Weekly review: New peanut patch data, norovirus outbreaks, and more
CDC: 2024-2025 seasonal norovirus outbreaks up from previous years
Based on reports by NoroSTAT-participating states, the total number of outbreaks in 2024-2025 seasonal year is above the range reported 012–2020 and 2021-2024 seasonal years.
Study: Nearly 80% of infants born in 2023-24 RSV season received RSV protection
The study within a single health care system revealed that most infants born prior to December received the nirsevimab monoclonal antibody.
Robert Frenk, MD: 2024 was big year for RSV prevention
Robert Frenck, MD, explained why 2024 was a big step in the right direction for RSV prevention, and emphasized the importance of vaccination against preventable diseases.
COVID-19 Roundtable: Prophylaxis for the immunocompromised
This week the panel weighs in on monoclonal antibodies in this patient population as well as important overall takeaways about COVID-19 therapies.
COVID-19 Roundtable: Considering off label therapies
This week, our experts weigh in on treatments not specifically indicated for COVID-19 treatment, including metformin, and concerns around using medications in this way.
Contemporary Pediatrics’ top 3 FDA approvals of 2024
From new topical dermatology treatments for atopic dermatitis to the first nasal spray to treat type 1 allergic reactions, these are our top FDA approvals of 2024.
FDA accepts BLA for clesrovimab to prevent RSV in infants' first RSV season
The federal agency has set a target action date of June 10, 2025 for potential approval.
Early HPV vaccination boosts completion rates
Early HPV vaccination at age 9 boosts completion rates, reduces disparities, and enhances cancer prevention effort, according to a recent study from Nemours Children's Health.
Pediatric RSV vaccine trial enrollment on hold in US, VRBPAC says
The halt follows a severe respiratory disease safety signal observed in a July 2024 phase 1 trial of Moderna's mRNA-1345 and mRNA-1365 vaccine candidates.
COVID-19 Therapy Roundtable: focusing on inpatient care
In this episode, the panel discusses therapies and care around inpatients including mechanical ventilation, extracorporeal membrane oxygenation (ECMO), and remdesivir.
A preview of the November/December issue of Contemporary Pediatrics
Editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, highlights the final Contemporary Pediatrics journal of the year.
Zelicapavir demonstrates antiviral effect in phase 2 RSV study
Zelicapavir demonstrated a favorable safety profile and was well-tolerated. The N-protein inhibitor has been granted Fast Track Designation by the FDA.
COVID-19 Therapy Roundtable: Defining the virus today and treatment options
In our latest roundtable series, we cover different therapies around COVID-19 treatment and prevention.